Aficamten shows significant benefits in exercise performance and safety for non-obstructive HCM patients, FDA submission planned.

Cytokinetics presented new data from the ACACIA-HCM trial showing that aficamten significantly improves exercise performance and symptoms in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The drug improved a novel composite exercise score and clinical outcomes, with manageable safety risks primarily during dose titration. These results support a planned supplemental New Drug Application to the FDA later this year, potentially expanding treatment options for nHCM patients.

As of Oct 13, 2026 03:11 WIB, Cytokinetics Inc (CYTK) trades at USD 61.86 on Pluang, down 1.67% for the day. The stock's market capitalization stands at $8.75 billion with a trading volume of 1,118,471 shares. The enterprise value is $8.85 billion, and the typical hold time on Pluang is 19 days, highlighting steady investor interest despite the slight daily decline.